Ophthalmologica

Original Paper

Effect of Photodynamic Therapy on Optical Coherence Tomography Angiography in Eyes with Chronic Central Serous Chorioretinopathy

Xu Y. · Su Y. · Li L. · Qi H. · Zheng H. · Chen C.

Author affiliations

Department of Ophthalmology, Renmin Hospital of Wuhan University, Wuhan, PR China

Keywords: Photodynamic therapyOptical coherence tomography angiographyChronic central serous chorioretinopathy

Related Articles for ""
Ophthalmologica 2017;237:167-172
https://doi.org/10.1159/000456676

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: March 27, 2016
Accepted: January 11, 2017
Published online: February 08, 2017
Issue release date: April 2017

Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 0

ISSN: 0030-3755 (Print)
eISSN: 1423-0267 (Online)

For additional information: https://www.karger.com/OPH

Abstract

Purpose: To analyze the use of optical coherence tomography angiography (OCTA) in order to observe the changes in chronic central serous chorioretinopathy (CCSC) after half-dose photodynamic therapy (PDT). Methods: This is a retrospective study evaluating an imaging technique in a cohort of patients. Fundus photography, fluorescein angiography (FA), indocyanine green angiography (ICGA) (Heidelberg Spectralis, Heidelberg, Germany), OCT, and OCTA with the split-spectrum amplitude-decorrelation angiography algorithm (XR Optovue, Fremont, CA, USA) were performed prior to half-dose PDT. OCT and OCTA were conducted at week 1, month 1, month 2, and month 3 after half-dose PDT. Results: A total of 33 eyes of 28 patients were enrolled in the study. At the baseline assessment, the patient pool had a mean best-correct visual acuity of logMAR 0.29 ± 0.34 and the mean choroidal thickness was 407.45 ± 77.98 µm. At month 3 after PDT, the patient pool had a mean best-correct visual acuity of logMAR 0.1 ± 0.17 and the mean choroidal thickness was 355.48 ± 67.90 µm. Abnormal flow in the choriocapillary, which corresponded to the initial examinations using OCTA, was observed in all 33 eyes (100%). The images show an irregular high pixel values interval from low pixel values. At week 1 after half-dose PDT, 25 eyes (75.8%) resembled the baseline images of the choriocapillary layer of OCTA. Areas of nonperfusion in the choriocapillary were observed in 5 eyes (15.2%), and vessel-like material in the choriocapillary was observed in 3 eyes (9.0%). At month 3 after PDT, the choriocapillary layer of OCTA was shown to return to normal in 32 eyes (97%). Conclusions: We have detected choriocapillary changes in patients diagnosed with CCSC following half-dose PDT by using noninvasive OCTA. These findings provide new evidence in support of the previously proposed hypothesis on the effect of PDT and suggest that OCTA may become a useful tool in the follow-up of CCSC.

© 2017 S. Karger AG, Basel



Related Articles:

References

  1. Guyer DR, Yannuzzi LA, Slakter JS, Sorenson JA, Ho A, Orlock D: Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol 1994;112:1057-1062.
  2. Yannuzzi LA: Type-a behavior and central serous chorioretinopathy. Retina 1987;7:111-131.
  3. Liegl R, Ulbig MW: Central serous chorioretinopathy. Ophthalmologica 2014;232:65-76.
  4. Lai TY, Chan WM, Li H, Lai RY, Liu DT, Lam DS: Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. Br J Ophthalmol 2006;90:869-874.
  5. Chan WM, Lai TY, Lai RY, Tang EW, Liu DT, Lam DS: Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina 2008;28:85-93.
  6. Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK: Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 2003;87:1453-1458.
  7. Jia Y, Bailey ST, Wilson DJ, Tan O, Klein ML, Flaxel CJ, Potsaid B, Liu JJ, Lu CD, Kraus MF, Fujimoto JG, Huang D: Quantitative optical coherence tomography angiography of choroidal neovascularization in age-related macular degeneration. Ophthalmology 2014;121:1435-1444.
  8. Jia Y, Tan O, Tokayer J, Potsaid B, Wang Y, Liu JJ, Kraus MF, Subhash H, Fujimoto JG, Hornegger J, Huang D: Split-spectrum amplitude-decorrelation angiography with optical coherence tomography. Opt Express 2012;20:4710-4725.
  9. Quaranta-El Maftouhi M, El Maftouhi A, Eandi CM: Chronic central serous chorioretinopathy imaged by optical coherence tomographic angiography. Am J Ophthalmol 2015;160:581-587.e1.
  10. Teussink MM, Breukink MB, van Grinsven MJ, Hoyng CB, Klevering BJ, Boon CJ, de Jong EK, Theelen T: OCT angiography compared to fluorescein and indocyanine green angiography in chronic central serous chorioretinopathy. Invest Ophthalmol Vis Sci 2015;56:5229-5237.
  11. Jia Y, Bailey ST, Hwang TS, McClintic SM, Gao SS, Pennesi ME, Flaxel CJ, Lauer AK, Wilson DJ, Hornegger J, Fujimoto JG, Huang D: Quantitative optical coherence tomography angiography of vascular abnormalities in the living human eye. Proc Natl Acad Sci USA 2015;112:E2395-E2402.
  12. Schmidt-Erfurth U, Laqua H, Schlotzer-Schrehard U, Viestenz A, Naumann GO: Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 2002;120:835-844.
  13. Chuang LH, Hwang YS, Wang NK, Chen YP, Liu L, Yeung L, Chen KJ, Chen TL, Wu WC, Lai CC: The chorioretinal damage caused by different half parameters of photodynamic therapy in rabbits. J Ocul Pharmacol Ther 2014;30:642-649.
  14. Yannuzzi LA, Freund KB, Goldbaum M, Scassellati-Sforzolini B, Guyer DR, Spaide RF, Maberley D, Wong DW, Slakter JS, Sorenson JA, Fisher YL, Orlock DA: Polypoidal choroidal vasculopathy masquerading as central serous chorioretinopathy. Ophthalmology 2000;107:767-777.
  15. Yang LH, Jonas JB, Wei WB: Conversion of central serous chorioretinopathy to polypoidal choroidal vasculopathy. Acta Ophthalmol 2015;93:e512-e514.
  16. Ahuja RM, Downes SM, Stanga PE, Koh AH, Vingerling JR, Bird AC: Polypoidal choroidal vasculopathy and central serous chorioretinopathy. Ophthalmology 2001;108:1009-1010.
  17. Chung SE, Kang SW, Lee JH, Kim YT: Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Ophthalmology 2011;118:840-845.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: March 27, 2016
Accepted: January 11, 2017
Published online: February 08, 2017
Issue release date: April 2017

Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 0

ISSN: 0030-3755 (Print)
eISSN: 1423-0267 (Online)

For additional information: https://www.karger.com/OPH

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2017, Vol.237, No. 3

April 2017

Article

Recommend This
TOP